Brain Cancer Trial, Recruiting NCT06776458 Sponsor: University of Toronto Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT06776458
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Case group (people with breast cancer):

  • People who are biologically female
  • People who have gone through natural menopause (periods stopped on their own, not due to surgical removal of both ovaries) and have had no periods for at least 1 year
  • People who have used hormone replacement therapy (HRT) for no more than 3 years total, and have not used it in the last 6 months
  • People who have been diagnosed with stage I, II, or III breast cancer
  • People whose breast cancer is hormone receptor positive and HER2 negative (ER+/PR+/HER2-)
  • People who are approximately 1 year past their breast cancer diagnosis and have received aromatase inhibitor therapy
  • People who are approximately 5 or 10 years past their breast cancer diagnosis and have received aromatase inhibitor therapy for at least 2 years
  • People who have already undergone surgery and/or radiation therapy for their breast cancer

Control group (people without breast cancer):

  • People who are biologically female
  • People who have gone through natural menopause (periods stopped on their own, not due to surgical removal of both ovaries) and have had no periods for at least 1 year
  • People who have used hormone replacement therapy (HRT) for no more than 3 years total, and have not used it in the last 6 months

Who may not be able to join:

  • People who have previously been treated with tamoxifen (a hormone therapy) before or around the time of menopause
  • People who have significant signs or symptoms of heart disease, diabetes, or kidney disease — including chest pain or discomfort, shortness of breath at rest or with light activity, dizziness or fainting, swollen ankles, irregular heartbeat, leg pain when walking, unusual tiredness with everyday activities, or a known heart murmur
  • People who have certain serious heart or circulatory conditions that make supervised maximum exercise testing unsafe, including previous heart attack, severe narrowing of major arteries, heart failure, blood clots in the lungs or legs, heart inflammation, uncontrolled irregular heartbeat, stroke, very high blood pressure (above 200/100 mmHg), or a cancer diagnosis other than skin cancer (confirm with trial site)
  • People who are unable to give informed consent or cannot communicate in English
  • People who have mobility limitations that would prevent exercise testing, such as using a wheelchair, walker, or having a significant limp
  • People who experience extreme claustrophobia

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 416-946-4069

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Toronto
Registry
ClinicalTrials.gov
Start date
1 February 2025
Est. completion
30 September 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Aortic Stiffness

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov